ALRT1057 data

ALRIZ announced interim results of a Phase I/II trial, showing a response in 13 of the first 43 treated patients (30 percent) on at least one of the AIDS Clinical Trial Group (ACTG) criteria, which include decrease in overall area of lesions and flattening of lesions, versus 4 of 43 patients responding (9 percent) in the control group.

No patient had a complete response, defined as resolution of all treated lesions. But 4.5 percent of the treated lesions had a complete clinical response versus no complete response in the controls. ...